PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Forecasted to Earn Q1 2023 Earnings of ($0.49) Per Share

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Get Rating) – Analysts at Oppenheimer decreased their Q1 2023 earnings per share estimates for shares of PMV Pharmaceuticals in a research report issued on Wednesday, March 1st. Oppenheimer analyst J. Jones now anticipates that the company will post earnings per share of ($0.49) for the quarter, down from their previous forecast of ($0.45). Oppenheimer has a “Outperform” rating and a $15.00 price target on the stock. The consensus estimate for PMV Pharmaceuticals’ current full-year earnings is ($1.89) per share. Oppenheimer also issued estimates for PMV Pharmaceuticals’ Q2 2023 earnings at ($0.50) EPS, Q3 2023 earnings at ($0.51) EPS, Q4 2023 earnings at ($0.44) EPS, FY2023 earnings at ($1.73) EPS, FY2024 earnings at ($1.80) EPS and FY2025 earnings at ($1.88) EPS.

Separately, HC Wainwright decreased their target price on PMV Pharmaceuticals from $63.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, November 17th.

PMV Pharmaceuticals Stock Performance

Shares of PMVP stock opened at $5.90 on Monday. The stock has a market cap of $270.04 million, a PE ratio of -3.64 and a beta of 0.99. The business’s fifty day moving average is $7.94 and its 200-day moving average is $10.33. PMV Pharmaceuticals has a 1 year low of $5.74 and a 1 year high of $24.26.

Hedge Funds Weigh In On PMV Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Bayesian Capital Management LP grew its position in PMV Pharmaceuticals by 5.8% during the third quarter. Bayesian Capital Management LP now owns 18,200 shares of the company’s stock worth $217,000 after buying an additional 1,000 shares in the last quarter. Legal & General Group Plc grew its position in PMV Pharmaceuticals by 14.9% during the second quarter. Legal & General Group Plc now owns 8,122 shares of the company’s stock worth $116,000 after buying an additional 1,055 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in PMV Pharmaceuticals by 7.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 15,613 shares of the company’s stock worth $222,000 after buying an additional 1,109 shares in the last quarter. Martingale Asset Management L P grew its position in PMV Pharmaceuticals by 7.6% during the third quarter. Martingale Asset Management L P now owns 21,276 shares of the company’s stock worth $254,000 after buying an additional 1,494 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in PMV Pharmaceuticals during the second quarter worth about $26,000.

About PMV Pharmaceuticals

(Get Rating)

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.